This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2001;285:1146.

	Since this article does not have an abstract, we have provided the first 94 words of the full text and any section headings.

The FDA has posted a proposal to disclose certain public health and safety data involved in all new and ongoing clinical studies on gene therapy and xenotransplantation (http://www.fda.gov/ohrms/dockets/98FR/011801b.htm). The proposal is intended to ensure greater public confidence in new therapeutic technologies and make FDA policy for public access to this information compatible with those of other government agencies. Written comments may be submitted until April 18, 2001, to the Dockets Management Branch, FDA, 5630 Fishers Lane, Rockville, MD 20852.

AUTHOR INFORMATION

Written inquiries may be directed to Jane E. Henney, MD, Commissioner of Food and Drugs, HF-1, Room 14–71, 5600 Fishers Ln, Rockville, MD 20857.

Bernard A. Schwetz, DVM, PhD
Acting Principal Deputy Commissioner
Food and Drug Administration